Reddy KS. Cardiovascular disease in non-Western countries. Coronary artery disease in the developing world. Ezzati M. How can cross-country research on health risks strengthen interventions? Circulation suppl I :I Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit.
Heart Attack Facts & Statistics | camentuxofeeds.gq
A two year experience with patients. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries GUSTO -IV substudy. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. B-type natriuretic peptide in the early diagnosis and risk stratification of acute chest pain.
Am J Med. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. Boggs W. Jul 11 The forgotten lead: does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients?.
Jul 3 Predictors of day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41, patients. Philadelphia, PA: Elsevier Saunders; Circadian and weekly variation and the influence of environmental variables in acute myocardial infarction. Neth Heart J. Clin Appl Thromb Hemost. Fever in myocardial infarction: is it still common, is it still predictive?. Cardiol J. Fever after acute myocardial infarction in patients treated with intravenous timolol or placebo.
Br Heart J. Evaluation of first-draw whole blood, point-of-care cardiac markers in the context of the universal definition of myocardial infarction: a comparison of a multimarker panel to troponin alone and to testing in the central laboratory. Arch Pathol Lab Med. Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem. Diagnostic accuracy of a point-of-care troponin I assay for acute myocardial infarction within 3 hours after presentation in early presenters to the emergency department with chest pain.
Mueller C. Biomarkers and acute coronary syndromes: an update. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Absolute and relative changes delta in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter trial. Diagnostic performance of cardiac troponin I for early rule-in and rule-out of acute myocardial infarction: Results of a prospective multicenter trial.
Login to your account
Delta troponin for the early diagnosis of AMI in emergency patients with chest pain. Int J Cardiol. A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. J Nucl Cardiol. Myocardial perfusion imaging in emergency department patients with negative cardiac biomarkers: yield for detecting ischemia, short-term events, and impact of downstream revascularization on mortality.
Circ Cardiovasc Imaging. Amgen Inc. FDA approves Amgen's Repatha evolocumab to prevent heart attack and stroke [press release]. December 1, ; Accessed: December 7, Evolocumab and clinical outcomes in patients with cardiovascular disease.
Heart attack (myocardial infarction)
Incidence of cardiac arrest during self-transport for chest pain. Ann Emerg Med. Wendling P.
Medscape Medical News. September 22, ; Accessed: March 26, Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts.
Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. Commentary: the role of percutaneous coronary intervention in ST-segment-elevation myocardial infarction. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Culprit versus multivessel coronary intervention in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
Coron Artery Dis. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than patients.
- LIVING IN ABUNDANCE;
- Stephanies Busy Day (Joy the Jellyfish).
- Myocardial Infarction: Practice Essentials, Background, Definitions.
- Heart attack (myocardial infarction) pathophysiology (video) | Khan Academy.
- Heart Attack (Myocardial Infarction) - Harvard Health!
White HD. Thrombolytic therapy in the elderly. Assessment of the Safety and Efficacy of a New Thrombolytic. A meta-analysis comparing percutaneous coronary intervention with drug eluting stents versus coronary artery bypass grafting in unprotected left main disease [in press]. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen ASSENT -3 PLUS randomized trial in acute myocardial infarction. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. The introduction of ticagrelor is associated with lower rates of recurrent ischemic stroke after myocardial infarction. PLoS One. Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. Am J Cardiovasc Drugs. Schnapf AJ. Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome. J Cardiovasc Nurs. Ryan TJ. Percutaneous coronary intervention in st-elevation myocardial infarction. Curr Cardiol Rep. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized trial of low molecular weight heparin enoxaparin versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study.